



HUTCHISON CHINA MEDITECH LIMITED

**Hutchison China MediTech Limited (“Chi-Med”)  
(AIM: HCM)**

**Directors’ Shareholding**

**London: Wednesday, 8 April 2015:** Chi-Med received notifications on 8 April 2015 that the following Directors have purchased ordinary shares of US\$1.00 each in Chi-Med (the “Shares”) as follows:-

Director	Date of purchase	Number of Shares purchased	Purchase price	Beneficial interest in Shares following purchases	
				Number of Shares	% of total issued share capital
Simon To (Executive Director and Chairman)	2 April 2015	10,000	GBP13.85	127,000	0.24%
	7 April 2015	48,000	GBP13.85		
Edith Shih (Non-executive Director and Company Secretary)	2 April 2015	10,000	GBP13.85	60,000	0.11%
	7 April 2015	2,000	GBP13.85		

**Ends**

**Enquiries**

**Chi-Med**  
Christian Hogg, CEO

Telephone: +852 2121 8200

**Panmure Gordon (UK) Limited**  
Richard Gray  
Andrew Potts

Telephone: +44 20 7886 2500

**Citigate Dewe Rogerson**  
Anthony Carlisle  
David Dible

Telephone: +44 20 7638 9571  
Mobile: +44 7973 611 888  
Mobile: +44 7967 566 919

**About Chi-Med**

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases. Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China. Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13). For more information, please visit: [www.chi-med.com](http://www.chi-med.com).